NASDAQ:ALKS
Alkermes plc Stock News
$24.68
+0.240 (+0.98%)
At Close: Apr 26, 2024
Baxter (BAX) to Report Q2 Earnings: What's in the Offing?
02:24pm, Monday, 25'th Jul 2022 Zacks Investment Research
Baxter's (BAX) second-quarter results are likely to reflect growth in its Medication Delivery and BioPharma Solutions businesses. Hillrom's products are likely to have boosted sales
Is a Beat in Store for Alkermes (ALKS) This Earnings Season?
01:56pm, Monday, 25'th Jul 2022
Alkermes' (ALKS) second-quarter 2022 results set to report earnings and revenues figures and provide updates on its portfolio of marketed drugs.
DaVita (DVA) to Report Q2 Earnings: What's in the Offing?
01:26pm, Monday, 25'th Jul 2022 Zacks Investment Research
Supply constraints, along with inflationary pressures, is likely to have weighed on DaVita's (DVA) second quarter's top line.
What's in Store for West Pharmaceutical (WST) in Q2 Earnings?
01:39pm, Friday, 22'nd Jul 2022 Zacks Investment Research
West Pharmaceutical's (WST) second-quarter results are likely to reflect strength in the Proprietary Products business.
Roche (RHHBY) 1H22 Earnings, Sales Grow, View Disappoints
04:04pm, Thursday, 21'st Jul 2022 Zacks Investment Research
Roche (RHHBY) performance in the first half was decent on demand for its diagnostics base business and new drugs. Demand for COVID-19 tests is likely to fall in the second half.
Vascular Biogenics (VBLT) Down, Ovarian Cancer Study Fails
03:49pm, Thursday, 21'st Jul 2022 Zacks Investment Research
Vascular Biogenics' (VBLT) phase III OVAL study, evaluating ofra-vec in patients with platinum-resistant ovarian cancer, fails to meet the primary endpoint.
Ecolab (ECL) to Report Q2 Earnings: What's in the Offing?
03:47pm, Thursday, 21'st Jul 2022 Zacks Investment Research
Ecolab's (ECL) second-quarter results are likely to reflect continued strength in its Global Industrial segment.
Stryker (SYK) to Report Q2 Earnings: What's in the Cards?
12:13pm, Thursday, 21'st Jul 2022 Zacks Investment Research
Stryker's (SYK) second-quarter results are likely to reflect strong segmental performances. However, the resurgence of COVID-19 infections is likely to have hurt sales growth.
3 Stocks With Momentum Anomaly to Buy on Solid Earnings Rally
10:47am, Thursday, 21'st Jul 2022 Zacks Investment Research
Alkermes plc (ALKS), BancFirst (BANF) and ExlService (EXLS) are currently witnessing a short-term pullback in price. So, make sure you take full advantage of it.
3 Stocks With Momentum Anomaly to Buy on Solid Earnings Rally
08:33am, Thursday, 21'st Jul 2022
Alkermes plc (ALKS), BancFirst (BANF) and ExlService (EXLS) are currently witnessing a short-term pullback in price. So, make sure you take full advantage of it.
Sorrento (SRNE) Rises on FDA IND Clearance for COVID Drug
03:10pm, Wednesday, 20'th Jul 2022 Zacks Investment Research
Sorento Therapeutics (SRNE) receives IND application clearance from the FDA for a phase I study evaluating STI-1558 for COVID-19.
Alkermes (ALKS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
02:01pm, Wednesday, 20'th Jul 2022 Zacks Investment Research
Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Incyte (INCY) Gets FDA Nod for Label Expansion of Opzelura
03:48pm, Tuesday, 19'th Jul 2022 Zacks Investment Research
Incyte (INCY) Opzelura cream 1.5% gets FDA approval for another indication - nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.
Novartis (NVS) Q2 Earnings Beat, Revenues Miss Estimates
02:37pm, Tuesday, 19'th Jul 2022 Zacks Investment Research
Novartis (NVS) reports mixed results in the second quarter, as key brands maintain momentum but generic competition remains a drag.
Roche (RHHBY) Announces 2-Year Data on Vabysmo for nAMD
05:35pm, Friday, 15'th Jul 2022 Zacks Investment Research
Roche's (RHHBY) new two-year data reinforce the long-term efficacy, safety and durability of Vabysmo in wet age-related mtacular degeneration.
